Author: Greenhawt, Matthew; Abrams, Elissa M.; Shaker, Marcus; Chu, Derek K.; Kahn, David; Akin, Cem; Alqurashi, Waleed; Arkwright, Peter; Baldwin, James L.; Ben-Shoshan, Moshe; Bernstein, Jonathan; Bingeman, Theresa; Blumchen, Katerina; Byrne, Aideen; Bognanni, Antonio; Campbell, Dianne; Campbell, Ronna; Chagla, Zain; Chan, Edmond S.; Chan, Jeffrey; Comberiatti, Pasquale; Dribin, Timothy E.; Ellis, Anne K.; Fleischer, David M.; Fox, Adam; Frischmeyer-Guerrerio, Pamela A.; Gagnon, Remi; Grayson, Mitchell H.; Horner, Caroline C.; Hourihane, Johnathan; Katelaris, Constance H.; Kim, Harold; Kelso, John M.; Lang, David; Ledford, Dennis; Levin, Michael; Lieberman, Jay; Loh, Richard; Mack, Doug; Mazer, Bruce; Mosnaim, Gissele; Munblit, Daniel; Mustafa, S Shahzad; Nanda, Anil; Oppenheimer, John; Perrett, Kirsten P.; Ramsey, Allison; Rank, Matt; Robertson, Kara; Shiek, Javed; Spergel, Jonathan M.; Stukus, David; Tang, Mimi LK.; Tracy, James M.; Turner, Paul J.; Whalen-Browne, Anna; Wallace, Dana; Wang, Julie; Wasserman, Susan; Witty, John K.; Worm, Margitta; Vander Leek, Timothy K.; Golden, David BK.
Title: The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach Cord-id: 9g6tw1za Document date: 2021_6_18
ID: 9g6tw1za
Snippet: Concerns for anaphylaxis may hamper SARS-CoV-2 immunization efforts. We convened a multi-disciplinary group of international experts in anaphylaxis comprised of allergy, infectious disease, emergency medicine, and front-line clinicians to systematically develop recommendations regarding SARS-CoV-2 vaccine immediate allergic reactions. Medline, EMBASE, Web of Science, the WHO global coronavirus database, and the grey literature (inception-March 19, 2021) were systematically searched. Paired revie
Document: Concerns for anaphylaxis may hamper SARS-CoV-2 immunization efforts. We convened a multi-disciplinary group of international experts in anaphylaxis comprised of allergy, infectious disease, emergency medicine, and front-line clinicians to systematically develop recommendations regarding SARS-CoV-2 vaccine immediate allergic reactions. Medline, EMBASE, Web of Science, the WHO global coronavirus database, and the grey literature (inception-March 19, 2021) were systematically searched. Paired reviewers independently selected studies addressing anaphylaxis after SARS-CoV-2 vaccination, polyethylene glycol (PEG) and polysorbate allergy, and accuracy of allergy testing for SARS-CoV-2 vaccine allergy. Random effects models synthesized the data to inform recommendations based on the GRADE approach, agreed upon using a modified Delphi panel. The incidence of SARS-CoV-2 vaccine anaphylaxis is 7.91 cases/million (n=41,000,000 vaccinations, 95%CI 4.02-15.59; 26 studies, moderate certainty), the prevalence of PEG allergy is 103 cases/million (95%CI 88-120; 2 studies, very low certainty), and the sensitivity for PEG skin testing is poor though specificity is high (15 studies, very low certainty). We recommend vaccination over either no vaccination or performing SARS-CoV-2 vaccine/excipient screening allergy testing for individuals without history of a severe allergic reaction to the SARS-CoV-2 vaccine/excipient, and a shared decision-making paradigm in consultation with an allergy specialist for individuals with a history of a severe allergic reaction to the SARS-CoV-2 vaccine/excipient. We recommend further research to clarify SARS-CoV-2 vaccine/vaccine excipient testing utility in individuals potentially allergic to SARS-CoV2 vaccines or their excipients.
Search related documents:
Co phrase search for related documents- additional study and administration vaccine: 1, 2, 3
- additional study and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- additional study and low certainty: 1, 2, 3, 4
- additional study and low middle: 1, 2, 3, 4, 5, 6, 7, 8, 9
- additional study and low number: 1, 2, 3
- additional vaccination and administration vaccine: 1, 2, 3, 4
- additional vaccination and local reaction: 1
- additional vaccination and logistic regression: 1, 2, 3, 4, 5, 6, 7
- additional vaccination and low middle: 1, 2
- additional vaccination and low middle income country: 1
- additional vaccination and low number: 1
- additional vaccine dose and administration vaccine: 1, 2
- additional vaccine dose and logistic regression: 1
- additional vaccine dose and long term protection: 1
- additional vaccine dose and low middle: 1
- adenoviral vector and logistic regression: 1, 2
- adenoviral vector and long term protection: 1
- adenoviral vector and low middle: 1
Co phrase search for related documents, hyperlinks ordered by date